RxDoctor Payments Data

Mayra Melendez, MD

Internal Medicine · Tucson, AZNPI 1255317327

Payments from drug & device makers

$2,340in general payments, 2019–2025

Across 138 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$456
  • AbbVie$335
  • AstraZeneca$159
  • Boehringer Ingelheim$159
  • Exact Sciences$154
  • Lilly USA, LLC$141
  • plus $935 from 18 others

What the payments were for

  • Food & beverage$2,340100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,340 in reported general payments places this provider in the 85th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$123,424
Medicare patients
282
Services billed
1,549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide128$167,527
TrulicityDulaglutide71$87,177
EliquisApixaban77$72,619
JanuviaSitagliptin Phosphate61$66,398
MounjaroTirzepatide48$65,147
JardianceEmpagliflozin42$56,551
FarxigaDapagliflozin Propanediol33$47,544
RybelsusSemaglutide16$24,039
Combivent RespimatIpratropium/Albuterol Sulfate23$11,846
Arnuity ElliptaFluticasone Furoate41$9,343
Advair HfaFluticasone Propion/Salmeterol20$7,309
Breo ElliptaFluticasone/Vilanterol16$7,061
LantusInsulin Glargine,hum.Rec.Anlog52$5,965
Atorvastatin Calcium568$5,838
Levothyroxine Sodium564$5,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Levemir$124$195,475159 claims
Lilly USA, LLCTrulicity, Mounjaro$141$152,324119 claims
PfizerEliquis$138$72,61977 claims
Boehringer IngelheimJardiance, Combivent Respimat$159$68,39865 claims
MerckJanuvia$54$66,39861 claims
AstraZenecaFarxiga, Symbicort$159$50,81447 claims
GSKArnuity Ellipta, Breo Ellipta$456$16,40557 claims
Sanofi-aventis U.S. LLCLantus$131$5,96552 claims
AbbVieSynthroid$335$2,00817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →